PMID- 26884290
OWN - NLM
STAT- MEDLINE
DCOM- 20170317
LR  - 20181202
IS  - 2299-8306 (Electronic)
IS  - 0423-104X (Linking)
VI  - 67
IP  - 2
DP  - 2016
TI  - The effect of hypolipidemic treatment on monocyte cytokine release in different 
      age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
PG  - 190-6
LID - 10.5603/EP.a2016.0021 [doi]
AB  - INTRODUCTION: Although both statins and fibrates have been found to reduce 
      monocyte cytokine release, no study has investigated whether the effect of 
      hypolipidaemic agents depends on age. MATERIAL AND METHODS: This study 
      retrospectively analysed the results of 65 patients with type 2 diabetes and 
      atherogenic dyslipidaemia, complying with lifestyle intervention, and receiving 
      metformin. These patients were then treated with simvastatin (40 mg daily), 
      micronized fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Tumour 
      necrosis factor-alpha (TNF-alpha), inteleukin-1beta, interleukin-6, and monocyte 
      chemoattractant protein-1 (MCP-1) release, as well as circulating levels of 
      high-sensitivity C-reactive protein (hsCRP), were determined separately for 
      patients aged between 20 and 50 years and between 51 and 75 years before the 
      study and after 12 weeks of hypolipidaemic treatment. RESULTS: Older adults were 
      characterised by higher monocyte release of TNF-alpha and interleukin-6, as well 
      as higher circulating levels of hsCRP, than the younger subjects. The decrease in 
      monocyte release of all investigated cytokines and in plasma hsCRP was similar in 
      both age groups. In turn, the effect of fenofibrate, alone or in combination with 
      simvastatin, on TNF-alpha, interleukin-6, and hsCRP, but not on interleukin-1beta 
      and MCP-1, was stronger in patients aged between 50 and 75 years, and correlated 
      with an improvement in insulin sensitivity only in this age group. CONCLUSIONS: 
      Our results suggest that age may partially determine monocyte-suppressing and 
      systemic anti-inflammatory effects of fenofibrate.
FAU - Krysiak, Robert
AU  - Krysiak R
AD  - Department of Internal Medicine and Clinical Pharmacology, Medical University of 
      Silesia, Katowice, Poland. r.krysiak@interia.pl.
FAU - Gdula-Dymek, Anna
AU  - Gdula-Dymek A
FAU - Marek, Bogdan
AU  - Marek B
FAU - Okopien, Boguslaw
AU  - Okopien B
LA  - eng
PT  - Journal Article
DEP - 20160217
PL  - Poland
TA  - Endokrynol Pol
JT  - Endokrynologia Polska
JID - 0370674
RN  - 0 (Cytokines)
RN  - 0 (Hypolipidemic Agents)
RN  - AGG2FN16EV (Simvastatin)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Atherosclerosis/blood/complications/drug therapy/metabolism
MH  - Cytokines/blood/drug effects/*metabolism
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Dyslipidemias/blood/complications/*drug therapy/metabolism
MH  - Female
MH  - Fenofibrate/therapeutic use
MH  - Humans
MH  - Hypolipidemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Monocytes/drug effects/*metabolism
MH  - Retrospective Studies
MH  - Simvastatin/therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - age
OT  - atherogenic dyslipidemia
OT  - cytokines
OT  - fenofibrate
OT  - monocytes
OT  - simvastatin
EDAT- 2016/02/18 06:00
MHDA- 2017/03/18 06:00
CRDT- 2016/02/18 06:00
PHST- 2015/06/11 00:00 [received]
PHST- 2015/08/10 00:00 [accepted]
PHST- 2015/07/27 00:00 [revised]
PHST- 2016/02/18 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2017/03/18 06:00 [medline]
AID - VM/OJS/J/42285 [pii]
AID - 10.5603/EP.a2016.0021 [doi]
PST - ppublish
SO  - Endokrynol Pol. 2016;67(2):190-6. doi: 10.5603/EP.a2016.0021. Epub 2016 Feb 17.